CDK6 and bladder transitional cell carcinoma: A study involving 31 urothelial carcinoma cases showed higher CDK6 expression levels in the BLCA tissues than in adjacent non-neoplastic tissues (9), suggesting that CDK6 could be a potential therapeutic target for urothelial carcinoma.